232 results about "Aminocaproic acid" patented technology

Cell-penetrating peptides useful for targeting a therapeutic compound to a selected mammalian tissue, methods for their identification, methods of forming conjugate compounds containing such peptides, and conjugates formed thereby are disclosed. The cell-penetrating peptides are 8 to 30 amino acid residues in length and consist of subsequences selected from the group consisting of RXR, RX, RB, and RBR; where R is arginine, B is β-alanine, and each X is independently —C(O)—(CHR1)n—NH—, where n is 4-6 and each R1 is independently H or methyl, such that at most two R1's are methyl. In one embodiment, X is a 6-aminohexanoic acid residue.

The present invention relates to a solid composition useful for tissue gluing, tissue sealing and haemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N / cm, density of 1-10 mg / cm<3>, chamber diameter of more than 0.75 mm and less than 4 mm and / or having a chamber diameter average below 3 mm and evenly distributed and fixed upon said carrier, b) solid fibrinogen, and c) solid thrombin.The carrier is a biodegradable polymer such as a polyhyaluronic acid, polyhydroxy acid, e.g. lactic acid, glucolic acid, hydroxybutanoic acid, a cellulose, gelatine or collagen, such as a collagen sponge, e.g. a collagen sponge consisting essentially of collagen type I fibres. The fibrinogen and thrombin are preferably human, purified from a natural source, or transgenic or recombinant human fibrinogen and / or thrombin. In a preferred embodiment the composition does not comprise any antifibronolytic agent such as aprotinin, epsilon-aminocaproic acid or alpha2-antiplasmin,

The present invention relates to a solid composition useful for tissue gluing, tissue sealing and hemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N / cm, density of 1-10 mg / cm3, chamber diameter of more than 0.75 mm and less than 4 mm and / or having a chamber diameter average below 3 mm and evenly distributed and fixed upon said carrier, b) solid fibrinogen, and c) solid thrombin.The carrier is a biodegradable polymer such as a polyhyaluronic acid, polyhydroxy acid, e.g. lactic acid, glucolic acid, hydroxybutanoic acid, a cellulose, gelatine or collagen, such as a collagen sponge, e.g. a collagen sponge consisting essentially of collagen type I fibers. The fibrinogen and thrombin are preferably human, purified from a natural source, or transgenic or recombinant human fibrinogen and / or thrombin. In a preferred embodiment the composition does not comprise any antifibronolytic agent such as aprotinin, ε-aminocaproic acid or α2-antiplasmin,

Aspects of the invention relate to methods for the production of difunctional alkanes in host cells. In particular, aspects of the invention describe components of genes associated with the difunctional alkane production from carbohydrate feedstocks in host cells. More specifically, aspects of the invention describe metabolic pathways for the production of adipic acid, aminocaproic acid, caprolactam, and hexamethylenediamine via 2-ketopimelic acid.

The present invention relates to a solid composition useful for tissue gluing, tissue sealing and hemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N / cm, density of 1-10 mg / cm3, chamber diameter of more than 0.75 mm and less than 4 mm and / or having a chamber diameter average below 3 mm and evenly distributed and fixed upon said carrier, b) solid fibrinogen, and c) solid thrombin. The carrier is a biodegradable polymer such as a polyhyaluronic acid, polyhydroxy acid, e.g. lactic acid, glucolic acid, hydroxybutanoic acid, a cellulose, gelatine or collagen, such as a collagen sponge, e.g. a collagen sponge consisting essentially of collagen type I fibres. The fibrinogen and thrombin are preferably human, purified from a natural source, or transgenic or recombinant human fibrinogen and / or thrombin. In a preferred embodiment the composition does not comprise any antifibronolytic agent such as aprotinin, ε-aminocaproic acid or α2-antiplasmin,

Disclosed is a polyamide resin which is produced by the polycondensation of (A) pentamethylenediamine, (B) terephthalic acid and / or a derivative thereof, and (C) at least one compound selected from adipic acid, azelaic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, isophthalic acid, 1,9-diaminononane, 1,10-diaminodecane, 1,11-diaminoundecane, 1,12-diaminododecane, caprolactam, undecalactam, laurolactam, aminocaproic acid, 11-aminoundecanoic acid, 12-aminododecanoic acid, and derivatives of these compounds. In the polyamide resin, the ratio of a repeating unit derived from the component (C) is 10 to 50 wt% (inclusive) relative to the total weight of the polymer. A solution of the polyamide resin in 98% sulfuric acid, which contains the polyamide resin at a concentration of 0.01 g / ml, has a relative viscosity of 1.5 to 4.5 at 25 DEG C.

Provided herein are linker compounds and conjugates that include the linker compounds. In one embodiment, the linker compounds comprise 2 or 3 residues of 6-aminohexanoic acid and optionally 7-10 residues of polyethyleneglycol (PEG). The linker compounds are useful in forming conjugates with one or more components useful in biopharmaceutical or bioanalytical applications. In particular, the biopharmaceutically useful compounds are kinase inhibitors. The conjugates described herein have utility in a variety of diagnostic, separation, and therapeutic applications.

A peptide of the formula Iwherein X is hydrogen, glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D-phenylalanine, D-tryptophan, gamma-aminobutyric acid or ζ-aminocaproic acid; A is D-gluptamic acid or D-y-glutamic acid; and Y is glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D-phenylalanine, D-tryptophn, gamma-aminobutyric acid, ζ-aminocaproic acid, hydroxyl, or an amide group.

The present invention relates to a bone-repairing composite polymer material containing a ceramic ingredient and a preparation method thereof. The bone-repairing composite polymer material is composed of the calcium phosphate ceramic ingredient and a polybasic amino acid polymer ingredient, wherein, the mass ratio of the calcium phosphate ceramic ingredient is between 5 percent and 30 percent, and the rest is the polybasic amino acid polymer ingredient. Epsilon-aminocaproic acid is polymerized with at least two other types of amine acids to form the polybasic amino acid polymer ingredient, wherein, the mole ratio of the epsilon-aminocaproic acid in the polybasic amino acid polymer ingredient is between 50 percent and 90 percent, and the rest is the other amine acids including aminoacetic acid, lactamic acid, phenylalanine, lysine and proline. Under the protection of a inert gas, the materials, the amine acids and the calcium phosphate, are sufficiently and uniformly dispersed into water and then heated, so that various forms of waters can be removed from the materials, and finally, the materials are polymerized in two steps, respectively under a temperature between 200 DEG C and 220 DEG C and a temperature between 230 DEG C and 250 DEG C. The bone-repairing composite polymer material, which has excellent mechanical property, bioactivity, biocompatibility and controllable degradation property, can be perfectly combined with the interface of the bone tissue, and moreover, the degradation product is non-toxic and non-irritant.

The invention discloses a method for preparing an organic ternary polycarboxylic acid dustless antirust additive 2,4,6-tri(amino caproyl)-1,3,5-triazine by adopting a one-pot method, which comprises the following steps of: ring-opening caprolactam with alkali to generate carboxylate of aminocaproic acid first; then performing a substitution reaction by the carboxylate of aminocaproic acid and cyanuric chloride; and finally, acidizing with hydrochloric acid to prepare derivatives of organic ternary polycarboxylic acid. The preparation method is free from a toxic organic solvent and employs common water as a solvent for reaction. The preparation method ha the advantages of simple process operation, low production cost and low environmental pollution and is more suitable for large scale industrial production.

A peptide of the formula IX-A-D-Trp-Ywherein X is hydrogen, glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D-phenylalanine, D-tryptophan, gamma -aminobutyric acid or xi -aminocaproic acid; A is D-gluptamic acid or D-y-glutamic acid; and Y is glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D-phenylalanine, D-tryptophn, gamma -aminobutyric acid, xi -aminocaproic acid, hydroxyl, or an amide group.

Processes to prepare 5-cyanovaleric acid or its ester are provided, by carbonylation of a pentenenitrile, wherein pentenenitrile is reacted with carbon monoxide and water and / or an alcohol in the presence of a catalyst system. The catalyst system contains:(a) a metal of Group VIII or a compound thereof and(b) a bidentate phosphine, arsine and / or stibine ligand, wherein the bidentate ligand has the general formula (I):R1R2-M1-R-M2-R3R4  (I) wherein M1 and M2 are independently P, As or Sb, R is a divalent organic bridging group, which bridging group comprises a chain of 3 to 5 atoms directly connecting the 2 phosphorus atoms, which chain consists of carbon atoms and optionally a nitrogen, oxygen or sulphur atom or a silano or dialkylsilicon group, which alkyl groups independently comprise from 1 to 4 carbon atoms, and R1–R4 represent the same or different optionally substituted tertiary alkyl groups,(c) an acid having a pKa less than 3, as measured at 18° C. in an aqueous solution.ε-caprolactam is also prepared by reduction of 5-cyanovaleric acid or ester obtained above to 6-aminocaproic acid or ester, and then cyclisation of the 6-aminocaproic acid or ester to ε-caprolactam.

A method for inhibiting and dissolving the deposits formed on caustic or alkaline scrubbers used in scrubbing acidic gases such as carbon dioxide, hydrogen sulfide, which are formed during the pyrolytic cracking of naphtha, ethane, and propane. The cracking operations produce certain oxygenated compounds such as vinyl acetate or acetaldehyde, which undergo polymerization under alkaline condition. The vinyl acetate on hydrolysis releases acetaldehyde under alkaline conditions. Amino acids such as 6 amino caproic acid and lactams such as epsilon caprolactam not only prevent but also dissolve the polymers formed by aldol condensation.

To provide a polyamide resin excellent in lasting thermal stability and having a high biomass ratio.A polyamide resin comprising adipic acid units, pentamethylenediamine units and 6-aminocaproic acid units as constituents, wherein the weight ratio of the sum of the adipic acid units and the pentamethylenediamine units to the 6-aminocaproic acid units is 97:3 to 75:25. The pentamethylenediamine is preferably one produced from lysine using lysine decarboxylase, lysine decarboxylase-producing cells or a treated product of the cells.

The present invention relates to a solid composition useful for tissue gluing, tissue sealing and haemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N / cm, density of 1-10 mg / cm3, chamber diameter of more than 0.75 mm and less than 4 mm and / or having a chamber diameter average below 3 mm and evenly distributed and fixed upon said carrier, b) solid fibrinogen, and c) solid thrombin. The carrier is a biodegradable polymer such as a polyhyaluronic acid, polyhydroxy acid, e.g. lactic acid, glucolic acid, hydroxybutanoic acid, a cellulose, gelatine or collagen, such as a collagen sponge, e.g. a collagen sponge consisting essentially of collagen type I fibres. The fibrinogen and thrombin are preferably human, purified from a natural source, or transgenic or recombinant human fibrinogen and / or thrombin. In a preferred embodiment the composition does not comprise any antifibronolytic agent such as aprotinin, epsi-aminocaproic acid or alpha2-antiplasmin,

The present invention provides a latanoprost ophthalmic solution which can be stored at room temperature and is excellent in stability. The ophthalmic solution according to the present invention is an ophthalmic solution comprising latanoprost, wherein latanoprost is stabilized to be stored at room temperature by at least one means selected from the following 1) and 2); 1) adjusting pH of the solution to 5.0 to 6.25 and 2) adding ε-aminocaproic acid to the solution.

Disclosed is a polyamide resin which is produced by the polycondensation of (A) pentamethylenediamin, (B) terephthalic acid and / or a derivative thereof, and (C) at least one member selected from adipic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, isophthalic acid, 1,9-diaminononane, 1,10-diaminodecane, 1,12-diaminododecane, caprolactam, undecalactam, laurolactam, aminocaproic acid, 11-aminoundecanoic acid, 12-aminododecanoic acid, and derivatives of these compounds. In the polyamide resin, the ratio of a repeating unit derived from the component (C) is 10 to 50 wt % (inclusive) relative to the total weight of the polymer. A solution of the polyamide resin in 98% sulfuric acid, which contains the polyamide resin at a concentration of 0.01 g / ml, has a relative viscosity of 1.5 to 4.5 at 25° C.

The invention discloses a process for preparing Quinclorac artificial semiantigen, artificial antigen, specific antibody and use thereof, wherein the preparation comprises, subjecting the dichloroquine (3,7-dichlorine-8-quinoline carboxylic acid) to sulfoxide chlorinated acylation, reacting with reanal and aminocaproic acid, thus obtaining semiantigen 4-(3,7-dichlorine-8-quinolineformyl) reanal or 6-(3,7-dichlorine-8-quinolineformyl) aminocaproic acid (QB or QC).

The invention discloses a preparation method of 6-aminocaproic acid which is a hemostatic. The preparation method is characterized in that caprolactam is dissolved in diluted hydrochloric acid, heated and refluxed to produce 6-aminocaproic acid hydrochloride which is neutralized by spherical macro-porous styrene type weak alkaline anion exchange resin, thereby acquiring the product after treatment. Compared with other preparation methods, the reaction condition of the method is mild, and metal ion can not be mixed easily, the method is more scientific and rational, the standard of the burn residue required by the original material quality can be realized more easily, white crystal can be obtained from the product without activated carbon decolorizing, the operation is simple, the synthesizing cost is reduced and mass production of the technology is more suitable.

The invention discloses a synthesis method of a specific salbutamol artificial antigen, belonging to the technical field of biological chemical engineering. The synthesis method disclosed by the invention comprises the following steps of: activating salbutamol through a formaldehyde solution, and connecting 6-aminocaproic acid in the ortho-position of a phenolic hydroxyl group to obtain a salbutamol hapten; and coupling a carboxyl group on the salbutamol hapten with an amino group on a carrier protein to obtain the salbutamol artificial antigen. The synthesis method disclosed by the invention can make up for the insufficiencies and defects of the existing salbutamol antigen synthesis technologies, the salbutamol artificial antigen with high specificity is obtained, the specificity of a produced antibody is high, and the sensitivity is high; and experimental results show that the antiserum titre of an animal immunized by using the salbutamol artificial antigen disclosed by the invention can achieve 80000, the detection limit is 0.5ng / mL, and the half-inhibitory concentration IC50 is 5ng / mL. The antigen or the antibody disclosed by the invention can be used for establishing an enzyme-linked immunosorbent analytical method and a colloidal gold test strip rapid assay method so as to rapidly detect the residues of the salbutamol in a food and further realize broad application prospects.

The invention relates to a synthesis method of a high-sensitivity carbendazol complete antigen, belonging to the technical field of biochemical engineering. In the method, a carboxylic hapten H1 is synthesized by reacting carbendazol analog 2-chlorobenzimidazole and 6-aminocaproic acid, and is coupled with a carrier protein to prepare an immunogen; and on the basis that the heterologous coating can further enhance the sensitivity of the antibody, the hapten H2 obtained by reacting the carbendazol analog aminochlorobenzimidazole and 6-aminocaproic acid is coupled with OVA to obtain the coupled substance which can be used as a coating source. The complete antigen prepared by the method appears a specific carbendazol antigenic determinant, thereby providing possibilities for screening out high-specificity carbendazol monoclonal antibodies. The generated antibody has the advantages of high specificity and high sensitivity, and can be used for establishing an enzyme linked immunosorbent assay analysis method and a colloidal gold test paper quick detection method, thereby being used for quickly detecting carbendazol residues in food.

A hemostatic textile material to stop bleeding comprising a dialdehyde cellulose (DAC) carrier wherein the degree of oxidation of the dialdehyde cellulose varies from about 1.5% to 12%; and a blood coagulation factor selected from the group consisting of chitosan and gelatin; the blood coagulation factor being chemically immobilized thereon; and further optionally comprising a bacteriolytic agent selected from the group consisting of a lysozyme enzyme, silver nitrate, and chlorhexidine; and further optionally comprising a selected component that prevents hemolysis, the component selected from the group consisting of tranexamic acid or ε-aminocaproic acid chemically immobilized thereon.

A segmented copolyamide and its production are disclosed. The copolyamide consists of any one of monomer 11-amino-hendecanoic acid, 12-amino-lauric acid and 6-amino acetic acid or hydantoinamine, glycine, propalanine, 8-aminocaprylic acid or octane lactam, 9-amino-nonoic acid or nonane lactam, 10-amino-qunane acid or quinane lactam, 11-amino-hendecanoic, dodecanoic lactam or 12-amino-lauric acid or 14-amino-tetradecoic acid. The process is carried out by copolymerization reacting the raw materials with their related preformed polymer. It achieves low cost, various nylon resin products and better properties.

The invention relates to lactic acid-amino acid copolyester amide and a preparation method thereof and relates to the technical field of the copolyester amide. The lactic acid-amino acid copolyester amide can be used for improving thermal stability and mechanical strength of a polylactic acid material, and also can be used as a compatibilizer in the blending of polylactic acid and nylon. The lactic acid-amino acid copolyester amide is prepared by copolymerization of any amino acid and lactic acid, wherein the monomer of any amino acid can be 11-amino undecanoic acid, 12-amino dodecanoic acid and 6-aminocaproic acid or caprolactam, glycine, aminopropionic acid, aminobutyric acid, 8-aminocaprylic acid or octane lactam, 9-aminononanoic acid or nonane lactam, 10-amino decenouc acid or decane lactam, dodecane lactam, 14-amino tetradecanoic acid. According to the lactic acid-amino acid copolyester amide and the preparation method thereof disclosed by the invention, the polylactic acid products are various, the thermal performances and the mechanical performances of the polylactic acid products are improved and the application range of the material is more extensive.

The invention discloses preparation methods and applications of a benzylpenicilloic acid artificial antigen and a benzylpenicilloic acid artificial antibody, and relates to a method for simply, quickly and effectively detecting penicillin G and a degradation product of penicillin G, namely benzylpenicilloic acid. The specific antibody to penicillin G and the degradation product of penicillin G, namely benzylpenicilloic acid, is prepared by designing and synthesizing a hapten and the artificial antigen of a penicillin veterinary drug penicillin G with a 6-aminocaproic acid molecular structure and a beta-lactam ring molecular structure, and the degradation product of penicillin G, namely benzylpenicilloic acid; a molecular specific antigenic determinant of the veterinary drug is highlighted; the chemosynthesis difficulty is overcome; and an immune animal induces to generate the specific antibody with very high affinity.

The invention relates to an injection moldable bone repair composite material and a preparation method and a using method thereof. The composite material is a powder material consisting of a copolymer of multiple amino acids and a sulfate component of calcium, the sulfate component of the calcium accounts for 60-95% of total weight of the component material, and the balance is the copolymer of the multiple amino acids. The sulfate component of the calcium comprises alpha-hemihydrated calcium sulfate which accounts for 15%-60% of the total weight of the composite material and the balance of other sulfates of the calcium. The copolymer of the multiple amino acids is formed by polymerizing epsilon-aminocaproic acid and at least two types of other amino acids, and the molar ratio of each amino acid in the other amino acids is not less than 1% of the total weight of the amino acids. When in preparation, an intermediate parent body is obtained by in-situ polymerization and composition of other sulfates of the calcium and the amino acid monomers under inert gas protection and heating, and the composite material is prepared by smashing and then being composed with the alpha-hemihydrated calcium sulfate. The composite material powder is mixed with curing liquid, and then the composite material can be used by injection. The composite material can be fast molded after the injection and has the strength which is equivalent to that of cancellous bone, good biocompatibility and adjustable degradation speed, thereby being applicable to fixation and repair of clinical orthopedic complicated and irregular traumas.

A chemically amplified resist composition comprising a base polymer and an amine quencher in the form of a β-alanine, γ-aminobutyric acid, 5-aminovaleric acid, 6-aminocaproic acid, 7-aminoheptanoic acid. 8-aminooctanoic acid or 9-aminononanoic acid derivative having an unsubstituted carboxyl group has a high contrast of alkaline dissolution in rate before and after exposure and forms a pattern of good profile at a high resolution, minimal roughness and wide DOF.

The present invention provides a method for making 6-aminocaproic acid as an active pharmaceutical ingredient. The method comprises: performing a hydrolysis procedure to have ε-caprolactam react with acid or base to generate a first reaction mixture, performing a modification procedure to have a solubility regulating agent reacts with 6-aminocaproic acid in the first reaction mixture to form a second reaction mixture including an aminocaproic acid intermediate, performing a separation procedure to have the intermediate separated from the second reaction mixture and performing a hydrogenation procedure to have the aminocaproic acid intermediate hydrogenated to form a 6-aminocaproic acid product.